TAMRA MORROW: Open Payments
NPI 1699006015 · ARDMORE, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$949 in 52 payments from 9 companies in 2025. Trend: 2023 $907 · 2024 $855 · 2025 $949
Food & beverage: $949
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $206 |
| Lilly USA, LLC | 6 | $173 |
| ABBVIE INC. | 14 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $138 |
| Supernus Pharmaceuticals, Inc. | 5 | $107 |
| Novo Nordisk Inc | 2 | $55 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $54 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: REXULTI, CAPLYTA, VRAYLAR, Qelbree, MOUNJARO, ZEPBOUND, Rybelsus, JOURNAVX.
Industry payments across OK — which companies pay providers there.
